Agios Pharmaceuticals (AGIO)

Executive Summary

Agios Pharmaceuticals is a biopharmaceutical company focused on developing therapies for genetically defined rare diseases, with a core expertise in cellular metabolism. Its lead product, Mitapivat (Pyrukynd), is a first-in-class pyruvate kinase activator approved for pyruvate kinase (PK) deficiency in adults and has shown strong commercial momentum. Agios is expanding Mitapivat's label into pediatric PK deficiency through two Phase 3 trials (NCT05175105 and NCT05144256) and exploring its potential in other indications such as moderate hepatic impairment. Beyond PK deficiency, the pipeline includes Tebapivat (AG-946), a pyruvate kinase activator in Phase 2 for myelodysplastic syndromes (MDS), and AG-181, a phenylalanine hydroxylase stabilizer in Phase 1 for phenylketonuria (PKU). With a valuation of approximately $1.7 billion, Agios represents a compelling opportunity in rare disease therapeutics, supported by a robust late-stage pipeline and multiple upcoming catalysts.

Upcoming Catalysts (preview)

• Q2 2027Mitapivat Phase 3 pediatric PK deficiency data readout80% success
• Q4 2026Tebapivat Phase 2 MDS data update60% success
• Q1 2027AG-181 Phase 1 PKU data readout70% success